Xammy Nguyenla, Eddie Wehri, Erik Van Dis, Scott B Biering, Livia H Yamashiro, Chi Zhu, Julien Stroumza, Claire Dugast-Darzacq, Thomas G W Graham, Xuanting Wang, Steffen Jockusch, Chuanjuan Tao, Minchen Chien, Wei Xie, Dinshaw J Patel, Cindy Meyer, Aitor Garzia, Thomas Tuschl, James J Russo, Jingyue Ju, Anders M Näär, Sarah Stanley, Julia Schaletzky
SARS coronavirus 2 (SARS-CoV-2) has caused an ongoing global pandemic with significant mortality and morbidity. At this time, the only FDA-approved therapeutic for COVID-19 is remdesivir, a broad-spectrum antiviral nucleoside analog. Efficacy is only moderate, and improved treatment strategies are urgently needed. To accomplish this goal, we devised a strategy to identify compounds that act synergistically with remdesivir in preventing SARS-CoV-2 replication. We conducted combinatorial high-throughput screening in the presence of submaximal remdesivir concentrations, using a human lung epithelial cell line infected with a clinical isolate of SARS-CoV-2...
November 2, 2022: Scientific Reports